The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 16, 2024
Filed:
Dec. 16, 2021
Applicants:
Muhammed Majeed, Bangalore, IN;
Kalyanam Nagabhushanam, East Windsor, NJ (US);
Lakshmi Mundkur, Bangalore, IN;
Inventors:
Muhammed Majeed, Bangalore, IN;
Kalyanam Nagabhushanam, East Windsor, NJ (US);
Lakshmi Mundkur, Bangalore, IN;
Assignee:
Sami-Sabinsa Group Limited, Bangalore, IN;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 36/9066 (2006.01); A23L 33/105 (2016.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/12 (2006.01); A61K 31/19 (2006.01); A61K 31/23 (2006.01); A61K 36/324 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61K 47/42 (2017.01); A61P 3/06 (2006.01); A61P 19/02 (2006.01); A61P 39/06 (2006.01);
U.S. Cl.
CPC ...
A61K 36/9066 (2013.01); A23L 33/105 (2016.08); A61K 9/0053 (2013.01); A61K 9/0056 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2054 (2013.01); A61K 9/2059 (2013.01); A61K 9/4866 (2013.01); A61K 31/12 (2013.01); A61K 31/19 (2013.01); A61K 31/23 (2013.01); A61K 36/324 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61K 47/42 (2013.01); A61P 3/06 (2018.01); A61P 19/02 (2018.01); A61P 39/06 (2018.01);
Abstract
The invention discloses compositions and methods comprising enriched Bisdemethoxycurcumin (BDMC) present not less than 20% w/w for use in inhibiting Receptor for Advanced Glycation End-Products (RAGE) expression in a subject with chronic-inflammatory condition. The composition further comprises β-amyrin palmitate (BAP). The invention also includes disclose the use of the above composition in the management of chronic inflammatory condition in a subject.